Works matching IS 01145916 AND DT 2025 AND VI 48 AND IP 2

Results: 8

Fracture-Related Safety Reporting of JAK Inhibitors: An Analysis from the WHO Global VigiBase: Fracture Risk of JAK Inhibitors: A. M.-De la Torre et al.

Published in:

Drug Safety, 2025, v. 48, n. 2, p. 191, doi. 10.1007/s40264-024-01490-w

By:

Martinez de la Torre, Adrian;
Clausen, Andreas Bech;
Burden, Andrea M.;
Weiler, Stefan

Publication type:

Article

Views on the Development and Use of a New Digital Adverse Drug Event Reporting Platform in Australia: A Qualitative Study: Views on an Adverse Drug Event Reporting Platform : E.A. Gebreyohannes et al.

Published in:

Drug Safety, 2025, v. 48, n. 2, p. 179, doi. 10.1007/s40264-024-01489-3

By:

Gebreyohannes, Eyob Alemayehu;
Thornton, Christopher;
Thiessen, Myra;
de Vries, Sieta T.;
Coombs, Gretchen;
Hwang, Indae;
Lim, Renly

Publication type:

Article

Teratogenic Risk Impact and Mitigation (TRIM): Study Protocol for the Development of a Decision Support Tool to Prioritize Medications for Risk Mitigation: Teratogenic Risk Impact and Mitigation (TRIM) Study Protocol: A. G. Winterstein et al.

Published in:

Drug Safety, 2025, v. 48, n. 2, p. 107, doi. 10.1007/s40264-024-01488-4

By:

Winterstein, Almut G.;
Ewig, Celeste L. Y.;
Wang, Yanning;
Smolinski, Nicole E.;
Toyserkani, Gita A.;
LaCivita, Cynthia;
Lackey, Leila;
Eggers, Sara;
Zhou, Esther H.;
Diaby, Vakaramoko;
Sarayani, Amir;
Thai, Thuy;
Maro, Judith C.;
Rasmussen, Sonja A.

Publication type:

Article

Challenges in the Implementation of EU Risk Minimisation Measures for Medicinal Products in Clinical Practice Guidelines: Mixed Methods Multi-Case Study: Challenges in Implementing EU Risk Minimisation Measures in Clinical Practice Guidelines: M. Møllebæk et al

Published in:

Drug Safety, 2025, v. 48, n. 2, p. 161, doi. 10.1007/s40264-024-01487-5

By:

Møllebæk, Mathias;
Gardarsdottir, Helga;
Bikou, Alexia-Georgia;
Kodrič, Ana;
Silva, Ana Marta;
Andersen, Armin;
Kontogiorgis, Christos;
Poplavska, Elita;
Ahmadizar, Fariba;
Dermiki-Gkana, Foteini;
Rutkovska, Ieva;
Vaz, Inês Ribeiro;
Kos, Mitja;
Barão, Paula;
Grupstra, Renske;
Alves, Teresa Leonardo;
Almarsdóttir, Anna Birna

Publication type:

Article

Incidence of Idiosyncratic Drug-Induced Liver Injury Caused by Prescription Drugs: Incidence of DILI Caused by Prescription Drugs: V. L. Chen et al.

Published in:

Drug Safety, 2025, v. 48, n. 2, p. 151, doi. 10.1007/s40264-024-01486-6

By:

Chen, Vincent L.;
Rockey, Don C.;
Bjornsson, Einar S.;
Barnhart, Huiman;
Hoofnagle, Jay H.

Publication type:

Article

Drug-Induced Hypouricemia: Drug-Induced Hypouricemia: C. B. Salem et al.

Published in:

2025

By:

Ben Salem, Chaker;
Agrebi, Myriam;
Sahnoun, Dhouha;
Fathallah, Neila;
Hmouda, Houssem

Publication type:

Literature Review

Investigation of the Role of Chemical Analysis in Causality Assessment of Herbal and Dietary Supplement-Induced Liver Injury: Role of Chemical Analysis in Causality Assessment: D. Halegoua-DeMarzio et al.

Published in:

Drug Safety, 2025, v. 48, n. 2, p. 143, doi. 10.1007/s40264-024-01484-8

By:

Halegoua-DeMarzio, Dina;
Navarro, Victor J.;
Davis, Ashley;
Ahmad, Jawad;
Avula, Bharathi;
Barnhart, Huiman;
Barritt IV, A. Sidney;
Bonkovsky, Herbert L.;
Chen, Vincent L.;
Choi, Gina;
Fontana, Robert J.;
Ghabril, Marwan S.;
Khan, Ikhlas;
Koh, Christopher;
Odin, Joseph;
Rockey, Don C.;
Rostami, Hoss;
Serrano, Jose;
Sherker, Averell H.;
Stolz, Andrew

Publication type:

Article

Safeguarding Patients in the AI Era: Ethics at the Forefront of Pharmacovigilance: Ethical Considerations for AI-Driven Pharmacovigilance: A. Jain et al.

Published in:

Drug Safety, 2025, v. 48, n. 2, p. 119, doi. 10.1007/s40264-024-01483-9

By:

Jain, Ashish;
Salas, Maribel;
Aimer, Omar;
Adenwala, Zahabia

Publication type:

Article